ABVC BioPharma Q1 net loss narrows 68% to $944K; eyes AI agriculture in Taiwan

ABVC BIOPHARMA, INC.

2025-Q1 EPS reported -$0.06

Net loss per share improved to $(0.06) from $(0.29) in Q1 2024.
Total operating expenses reduced 76% to $693,005.
Net loss attributable to ABVC was $842,075, down from $2.83M.
Recognized a land asset in Taiwan valued at $7.67M for potential AI-integrated GAP-compliant plant factory.
Company evaluating development of AI-driven agricultural facility for sustainable botanical supply chain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.